Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine. (2023)
Attributed to:
'REBRACOVID' - multicentre cohort study of the natural history and immunology of COVID-19 in Brazil
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1053/j.gastro.2022.10.010
PubMed Identifier: 36270334
Publication URI: http://europepmc.org/abstract/MED/36270334
Type: Journal Article/Review
Volume: 164
Parent Publication: Gastroenterology
Issue: 2
ISSN: 0016-5085